This article is part of our special report Risk vs. hazard in policymaking.
SPECIAL REPORT / Groups campaigning to ban genetically modified foods in Europe have jumped on the recent discovery of unauthorised GM strain of wheat on an American farm as vindication of their longstanding campaign to banish biotech crops from the EU.
The European Commission will test US wheat imports for a strain of herbicide-resistant wheat developed by Monsanto, a global leader in agricultural biotechnology, but never approved by food regulators in the United States.
Any contaminated wheat would be banned, the Commission said.
Health and environmental campaign groups seized the discovery of the glyphosate-resistant strain to call for European-wide restrictions and to reverse policies that give national governments leeway over approving the sale and cultivation of GM crops.
The case could have implications well beyond the emotionally-fraught debate over biotech cultivation and food safety, with GM crops likely to be a sticking point in negotiations over a future of EU-US trade talks.
MEPs have weighed in with a resolution, adopted on 23 May, saying that the EU should not abandon the precautionary principle in its regulation of GM crops and animal cloning during the forthcoming trade talks.
“This is again another example of the need to have strict control systems, the need to have regulatory systems which are real, not like in the United States,” Marco Contiero, agricultural policy director for Greenpeace Europe, said of the case involving Monsanto’s MON71800 wheat.
Philip Miller, Monsanto’s vice president for regulatory affairs, said in a statement that the US-based company was co-operating with the US Department of Agriculture’s inspection unit, as well as regulators in the EU, Japan, Korea and Taiwan and has provided the European Commission with the information needed to test for the wheat.
Contiero welcomed Monsanto’s response and its recent announcement that it was not seeking approval of any new GM seeds in Europe for the time being, citing lack of demand and national bans on its MON810 maize.
Focus on conventional products
Monsanto will continue to focus on conventional products and provide biotech seeds to EU countries that allow them, said Brandon Mitchener, a company spokesman in Brussels. Its main rivals, including divisions of Germany’s BASF and Bayer and Syngenta in Switzerland, have also announced plans to focus their GM operations on markets other than Europe.
But Contiero said the moves by corporations do not reduce the risks nor the need for tighter regulation in the EU, though he said Greenpeace did not oppose GM research in “closed industrial environments.”
“The very simple fact that there are some different voluntary decisions taken by individual companies does not mean there is now no more the need to strengthen the current regulatory system,” Contiero told EURACTIV.
“Voluntary agreements are by nature very temporary. Monsanto itself said that as soon as they see more market acceptance, they would be very happy to sell their products in other countries,” he said.
Europe is far more wary of GM crops than the United States, which approved the first bio-engineered plant seed 19 years ago. Greenpeace and other European health and environmental groups argue that that scientific studies have yet to show conclusive evidence that there are no risks, to humans and the environment, from genetic modification, nor that there is any proof that biotech crops are more resistant to insects and drought.
Several EU states – Austria, Bulgaria, France, Greece, Hungary, Germany and Luxembourg – ban the sale and cultivation of GM crops yet environmental groups contend that an EU-wide ban is needed to prevent mixing GM and conventional crops.
The case involving the errant wheat crops in the western state of Oregon is likely to energise such arguments.
In the United States, several farmers have filed class-action lawsuits in federal courts against Monsanto, saying the company failed to protect wheat from contamination.
A case of ‘déjà vu’
The British activist group GM Freeze says the Oregon case mirrors the 2006 contamination of US long grain rice by Bayer’s experimental LL601 rice strain.
“There is a real sense of déjà vu about this situation after the very costly and disruptive incident involving US GM rice in 2006,” said Pete Riley, a campaigner for the British GM freeze group.
“European and UK regulators should take careful note of what has happened in Oregon,” Riley said in a statement. “GM Freeze has repeatedly pointed out that coexistence of GM and non-GM crops without contamination is almost impossible because of the difficulties in containing GM pollen and seeds and the fact that human error can never be eliminated. So far biotech companies refuse to accept liability for the contamination they cause, so farmers suffering economic losses have to go to court to get help.”
Europe’s conventional and GM business accounted for nearly 13% of Monsanto’s global market in 2012, or €1.3 billion in sales. Most of its GM business is the Czech Republic, Portugal, Romania, Slovakia and Spain, states that have been less reticent than other EU countries in embracing biotech farming.
An industry retreat from GM sales in Europe would go against trends in much of the rest of the world. Outside North America, Argentina, Brazil, India have been quick to embrace GM crops to address rising demand for food and biolfuel production. GM crops are now commercially grown in 22 nations, UN Food and Agriculture Organization (FAO) figures show, and GM seeds fall under an international treaty ratified by 161 countries – the Cartagena Protocol on Biosafety.
The FAO has also recognised the potential of GM crops to improve food security in developing nations, saying in a recent report: “Biotechnology promises to boost productivity and thus raise rural incomes, much in the same way that the green revolution did in large parts of Asia during the 1960s to 1980s.”
Growing demand for GM crops
Developing countries in South Asia and Africa are major growth markets, with the number or hectares under cultivation rising seven-fold in a decade, from 10 million in 2000 to 70 million in 2010, UN figures show. In advanced countries, cultivation in the same period grew from 30 million hectares to more than 70 million.
Despite campaign group concerns, the industry has long defended GM crops as safe to humans and ecosytems, saying that have weathered countless safety reviews by government regulators and scientific panels, including those advising the European Food Safety Authority (EFSA).
The World Health Organisation , reflecting similar findings by EFSA, has determined that existing GM foods “have passed risk assessments and are not likely to present risks for human health.”
Still, the GM debate often gives way to different sides accusing one another of shoddy science. Last October, a French study found that rats fed on a diet containing Monsanto’s NK603 – a maize seed variety doused with Roundup weedkiller – or given water with Roundup at levels permitted in the United States, died earlier than those on a standard diet.
The study by University of Caen researchers, who released photos of deformed and bloated rats to illustrate their findings, was immediately called into doubt. The European Commission requested a review of the controversial study and nine days later, EFSA issued a preliminary report saying that the research was “of insufficient scientific quality.”
EFSA is itself often the target of criticism, with campaign groups and EU governments accusing the agency of sidelining the precautionary principle and being too cozy with the very industries it is supposed to be evaluating.
In February 2012, a report by two campaign groups, the Corporate Europe Observatory and the Earth Open Source, said the EU agency repeatedly relied on industry scientists and information in risk assessments that are used by EU institutions and national governments.
“Too often it’s not independent science that underlies EFSA decisions about our food safety, but industry data,” says the report ‘Conflicts on the menu’.